A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Eligibility Criteria

• * Have received any prior treatment with enfortumab vedotin, tisotumab vedotin or other MMAE based or nectin-4 targeted antibody-drug conjugates.
• * Unstable CNS metastasis requiring treatment in the last 28 days.
• * Acute infection requiring IV treatment in the last 14 days.
• * Grade ≥2 peripheral neuropathy.
• * Pregnant or breastfeeding women.
• * Life-threatening illness or uncontrolled medical conditions that could compromise the subject's safety or put the study outcomes at risk
• * Any systemic anticancer therapy in the last 28 days prior to first administration of study drug.
• * Active HCV, HBV or HIV infection unless well controlled with anti-viral therapy.
• * Active or chronic corneal disorder, keratitis, corneal ulcerations or Sjogren's syndrome.
• * Have any ongoing acute inflammatory skin disease or chronic skin disease not well controlled.
• * Have been diagnosed with another primary malignancy except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or subjects with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
• * Have significant, uncontrolled or active cardiovascular disease
• * Have active or a history of pneumonitis or interstitial lung disease that requires corticosteroid treatment. Patients with radiation pneumonitis that does not require treatment is allowed.
• * Have uncontrolled diabetes.
• * Have received any strong CYP3A4 inhibitors within 14 days prior to the first dose of study drug.
• * Subjects known to be hypersensitive to bulumtatug fuvedotin or to any components of the formulation.
• * History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening.
• * Have received a live vaccine within 30 days of planned start of study therapy.